Covalon Technologies Ltd (TSE:COV)
:COV
Want to see TSE:COV full AI Analyst Report?
Top Page
Covalon Technologies
(COV)
Select Model
Select Model
Rating:65Neutral
Price Target:
C$2.50
▲(42.86% Upside)
Action:Reiterated
Date:05/22/26
The score is driven by solid financial stability (low leverage) and positive cash generation, plus constructive technical uptrend signals. These positives are partially offset by compressed TTM profitability and a steep valuation (very high P/E) with no dividend support.
Positive Factors
Conservative balance sheet
Very low leverage (debt-to-equity ~0.08 TTM) and a sizable equity base provide durable financial flexibility. This reduces refinancing and solvency risk, supports R&D and manufacturing investments, and preserves optionality to pursue partnerships or absorb demand shocks over the next several quarters.
Negative Factors
Margin compression
A marked gross margin decline from ~61% to ~52% TTM is a durable headwind to profitability. Unless cost structure or pricing is addressed, lower gross margins constrain operating leverage, reduce free cash flow potential, and make consistent margin recovery difficult over several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Very low leverage (debt-to-equity ~0.08 TTM) and a sizable equity base provide durable financial flexibility. This reduces refinancing and solvency risk, supports R&D and manufacturing investments, and preserves optionality to pursue partnerships or absorb demand shocks over the next several quarters.
Read all positive factors
Covalon Technologies (COV) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$59.66M
Dividend YieldN/A
Average Volume (3M)17.17K
Price to Earnings (P/E)36.3
Beta (1Y)0.31
Revenue Growth-3.44%
EPS Growth-57.64%
CountryCA
Employees105
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.06
Shares Outstanding27,618,076
10 Day Avg. Volume12,083
30 Day Avg. Volume17,167
Financial Highlights & Ratios
PEG Ratio-0.88
Price to Book (P/B)1.87
Price to Sales (P/S)1.75
P/FCF Ratio34.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$2.90Price Target Upside65.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.07
Revenue Forecast (FY)C$36.36M
Covalon Technologies Business Overview & Revenue Model
Company Description
Covalon Technologies Ltd., a Canadian company based in Mississauga, innovates, develops, manufactures, and commercializes medical technologies and products globally. Its operations span major international markets, including North America, Europe,...
How the Company Makes Money
Covalon makes money primarily by selling its medical device products (notably advanced wound care dressings and infection-prevention/protection products for medical devices) to healthcare providers and through distribution channels in its served m...
Covalon Technologies Earnings Call Summary
Earnings Call Date:Aug 21, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Aug 31, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted strong sequential revenue growth, successful international expansion, and a robust cash position, indicating positive forward momentum. However, year-over-year revenue decline and decreased adjusted EBITDA present concerns, although these may be offset by promising innovations and clinical study results.Positive Updates
Sequential Revenue Growth
Revenue at $8.4 million was up more than 10% sequentially between Q3 and Q2, led by more than 40% sequential quarterly growth in the U.S. advanced wound care sales channel.
Negative Updates
Decline in Year-Over-Year Revenue
Q3 revenue came in 9% below last year's Q3, which was their highest revenue quarter of 2024.
Read all updates
Q3-2025 Updates
Positive
Negative
Sequential Revenue Growth
Revenue at $8.4 million was up more than 10% sequentially between Q3 and Q2, led by more than 40% sequential quarterly growth in the U.S. advanced wound care sales channel.
Read all positive updates
Company Guidance
During Covalon's Q3 Fiscal 2025 conference call, CEO Brent Ashton provided optimistic guidance, emphasizing key financial and operational metrics. The company reported $8.4 million in revenue for Q3, marking a sequential increase of over 10% from Q2, driven by more than 40% growth in its U.S. advanced wound care sales. Despite a year-over-year revenue decline of 9% for Q3, the company achieved an adjusted EBITDA of nearly $1 million, reflecting a 50% increase from the previous quarter. Ashton highlighted a robust 13% growth in trailing 12-month revenue and a 27% compounded annual growth rate over three years, illustrating Covalon's market success. Additionally, the company maintained a strong cash position of over $18 million, up almost $9 million from the previous year. Operationally, Covalon achieved 100% retention of its top 50 U.S. hospital customers and added 15 new hospital accounts in Q3, with a total of 65 new accounts for the year. Ashton also shared promising updates on the company's innovation pipeline and international market expansion, including new product registrations and distribution agreements.Covalon Technologies Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
80
Positive
Cash Flow
71
Positive
| Breakdown | TTM | Sep 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 32.68M | 32.82M | 31.17M | 26.60M | 18.15M | 19.56M |
| Gross Profit | 17.31M | 17.47M | 18.93M | 14.36M | 7.49M | 9.70M |
| EBITDA | 2.09M | 3.01M | 3.14M | -3.56M | -8.11M | 1.54M |
| Net Income | 1.64M | 2.06M | 2.67M | -4.46M | -9.66M | 23.48M |
Balance Sheet | ||||||
| Total Assets | 33.18M | 36.12M | 31.81M | 24.90M | 30.38M | 40.58M |
| Cash, Cash Equivalents and Short-Term Investments | 16.57M | 17.37M | 16.75M | 8.79M | 14.06M | 22.95M |
| Total Debt | 1.77M | 2.25M | 901.67K | 1.56M | 2.17M | 2.59M |
| Total Liabilities | 5.16M | 5.40M | 4.30M | 6.11M | 6.15M | 7.21M |
| Stockholders Equity | 28.02M | 30.73M | 27.50M | 18.79M | 24.23M | 33.37M |
Cash Flow | ||||||
| Free Cash Flow | 4.71M | 1.65M | 3.06M | -4.50M | -9.08M | 443.71K |
| Operating Cash Flow | 6.09M | 2.29M | 3.47M | -3.18M | -7.99M | 621.37K |
| Investing Cash Flow | -1.55M | -847.02K | -281.63K | -81.02K | -843.02K | -278.53K |
| Financing Cash Flow | -4.87M | -529.35K | 4.97M | -2.16M | -2.19M | -8.25M |
Covalon Technologies Technical Analysis
Positive
1.75
Price Trends
1.97
Positive
1.84
Positive
1.91
Positive
Market Momentum
0.05
Positive
56.56
Neutral
61.73
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:COV, the sentiment is Positive. The current price of 1.75 is below the 20-day moving average (MA) of 2.07, below the 50-day MA of 1.97, and below the 200-day MA of 1.91, indicating a bullish trend. The MACD of 0.05 indicates Positive momentum. The RSI at 56.56 is Neutral, neither overbought nor oversold. The STOCH value of 61.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:COV.
Covalon Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | C$59.66M | 36.34 | 3.31% | ― | -3.44% | -57.64% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | C$52.16M | -4.08 | ― | ― | ― | 58.58% | |
42 Neutral | C$29.90M | -2.79 | -103.51% | ― | ― | 57.98% | |
42 Neutral | C$42.10M | -11.98 | ― | ― | -31.89% | 21.88% | |
41 Neutral | C$37.89M | -4.65 | ― | ― | ― | -40.15% |
* Healthcare Sector Average
TSE:COV
Covalon Technologies
2.16
-0.03
-1.37%
TSE:MDNA
Medicenna Therapeutics Corp
0.44
-0.48
-52.20%
TSE:MIR
Medmira
0.06
-0.02
-25.00%
TSE:SVA
Sernova
0.15
-0.02
-9.09%
TSE:NRX
NurExone Biologic
0.59
-0.18
-23.38%
TSE:DTC
Defence Therapeutics
0.50
-0.30
-37.50%
Covalon Technologies Corporate Events
Business Operations and Strategy
Covalon Builds Momentum in Vascular Access, Infection Prevention and Wound Care
Positive
Apr 15, 2026
Covalon Technologies has reported a series of commercial and market-development milestones that underscore rising demand for its vascular access and infection-prevention solutions. At the recent Infusion Nurses Society Annual Meeting, the company ...
Business Operations and StrategyProduct-Related Announcements
Covalon Highlights Infection Prevention Leadership at Infusion Nurses Society 2026 Meeting
Positive
Apr 10, 2026
Covalon Technologies will showcase its vascular access and infection prevention solutions at the Infusion Nurses Society 2026 Annual Meeting in Louisville, highlighting the growing adoption of its VALGuard Vascular Access Line Guard and CovaClear ...
Business Operations and StrategyExecutive/Board Changes
Covalon Grants Deferred Share Units to Directors Under Updated Incentive Plan
Positive
Mar 27, 2026
Covalon Technologies has granted 97,674 deferred share units to four non-employee directors who chose to receive all or part of their fiscal 2026 board fees in equity rather than cash. The awards, issued under the firm’s recently updated lon...
Business Operations and StrategyShareholder Meetings
Covalon Shareholders Approve All Resolutions at 2025 Annual Meeting
Positive
Mar 26, 2026
Covalon Technologies reported that shareholders approved all matters at its fiscal 2025 annual general and special meeting held on March 25, 2026, with 36.777% of shares represented. Resolutions passed included the election of the board, reappoint...
Business Operations and StrategyRegulatory Filings and ComplianceShareholder Meetings
Covalon Sets Virtual-Only Annual Shareholder Meeting for March 25, 2026
Neutral
Mar 18, 2026
Covalon Technologies plans to hold its annual meeting of shareholders on March 25, 2026, at 2:00 p.m. Eastern Time in a virtual-only format accessible via live webcast. The event will feature a presentation by CEO Brent Ashton followed by a questi...
Business Operations and StrategyShareholder Meetings
Covalon Sets Virtual-Only Annual Shareholder Meeting for March 25, 2026
Neutral
Mar 18, 2026
Covalon Technologies will hold its annual shareholder meeting on March 25, 2026, at 2:00 p.m. Eastern Time in a virtual-only format, allowing shareholders to attend and vote online via live webcast. The event will feature a presentation from CEO B...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.